Premier Alternatives

Mediar Therapeutics

Boston, MA · Founded 2018 · Privately Held (backing)

Developer of innovative fibrosis treatment intended for halting and reversing fibrotic activity. Mediar Therapeutics is based in Boston, MA and was founded in 2018. It was valued at $230 million at its later-stage round in Dec 2025, the last priced event on record. It has raised $180 million across 3 recorded rounds; the latest was a $37.8 million early-stage round in Dec 2025.

PMV mark · valuation
$230.0M
Oct 2026
Priced at
its later-stage round
Dec 2025
Total raised
$180.3M
Last round
Early Stage VC
Dec 2025

Mediar Therapeutics key facts

as of Oct 2026
  • Developer of innovative fibrosis treatment intended for halting and reversing fibrotic activity.
  • Mediar Therapeutics is valued at approximately $230.0M as of Oct 2026, set at its later-stage round, Dec 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $180.3M across 3 recorded rounds; the latest was Early Stage VC ($37.8M) in Dec 2025.
  • Notable investors include Kinled Holding, Sofinnova Partners, Mission BioCapital, ShangBay Capital, Pfizer Ventures — 21 tracked in total.
  • Mediar Therapeutics has filed 4 Form Ds with the SEC since 2019, most recently Oct 2024 ($85.0M sold to 17 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
MEDIUM confidence
$230.0M

Valued at $230.0M at its later-stage round, Dec 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Mediar Therapeutics with a free account
  • ·The complete investor list: 21 names
  • ·Watch Mediar Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Mediar Therapeutics funding rounds

3 rounds
Dec 2025Early Stage VC$37.8MSEC filing▮
Nov 2022Later Stage VC$85.0MSEC filing▮
Jan 2019Early Stage VC$5.0MSEC filing▮
Full funding history →

Mediar Therapeutics valuation

Mediar Therapeutics was valued at $230 million at its later-stage round in Dec 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Mediar Therapeutics raised?

Mediar Therapeutics has raised $180 million across 3 recorded rounds since 2019. The largest was an $85 million later-stage round in Nov 2022; the most recent was a $37.8 million early-stage round in Dec 2025.

Mediar Therapeutics has filed 4 Form Ds with the SEC since 2019, most recently in Oct 2024 ($85 million sold to 17 investors).

Mediar Therapeutics investors

21 investors are on record for Mediar Therapeutics, including Kinled Holding, Sofinnova Partners, Mission BioCapital and ShangBay Capital. The early-stage round in Dec 2025 drew 18 investors.

About Mediar Therapeutics

Developer of innovative fibrosis treatment intended for halting and reversing fibrotic activity. The company utilizes antibodies to neutralize mediators that contribute to the development of chronically damaged organs, thereby improving patient outcomes and advancing therapeutic options, enabling medical practitioners to address late-stage disease with precision and efficacy.

Sector
Healthcare
HQ
Boston, MA, United States
Founded
2018
Employees
49
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.